26^th Global Nephrology, Urology and Kidney Failure Congress

Role of Pharmacotherapy in Nephrology

Pharmacotherapy plays a crucial role in the management of kidney diseases, offering targeted interventions to slow progression, alleviate symptoms, and prevent complications. For chronic kidney disease (CKD), medications such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are essential in controlling blood pressure and providing renal protection. Additionally, erythropoiesis-stimulating agents (ESAs) are used to manage anaemia, a common complication of CKD. The management of mineral and bone disorders in CKD often involves phosphate binders and vitamin D analogues to maintain mineral balance. In cases of end-stage renal disease (ESRD), pharmacotherapy extends to managing dialysis-related complications and optimizing transplant outcomes. Emerging therapies, including SGLT2 inhibitors, have shown promise in both diabetic and non-diabetic kidney disease, indicating a shift toward more personalized approaches. However, careful consideration of drug interactions, especially in patients with multiple comorbidities, is essential. Ongoing research into novel pharmacological agents and treatment regimens continues to evolve, with the goal of improving outcomes and quality of life for individuals with kidney disease.